Schering New Zealand
Schering New Zealand is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Schering New Zealand.
Schering New Zealand is a company.
Key people at Schering New Zealand.
Schering New Zealand refers to entities associated with the New Zealand operations of the former global pharmaceutical giant Schering-Plough Corporation, primarily SCHERING NZ LIMITED and Schering Plough Animal Health Ltd.[4][6][8]. These were not investment firms or tech startups but subsidiaries focused on pharmaceutical and animal health products, distributing drugs like antibiotics, allergy treatments, and veterinary products derived from the parent company's portfolio.[1][2][6]. SCHERING NZ LIMITED, registered in 1958 as a NZ Limited Company, was removed from the register, indicating it is no longer active, while animal health operations linked to sites like 33 Whakatiki Street in Upper Hutt transitioned to MSD Animal Health.[4][8].
The parent Schering-Plough manufactured prescription drugs (e.g., Claritin for allergies, Garamycin antibiotics), consumer products (e.g., Coppertone sun care, Dr. Scholl’s foot care), and animal health items like Nuflor for bovine respiratory disease, serving human and veterinary markets globally including New Zealand.[1][2][3].
Schering New Zealand traces its roots to Schering AG, founded in 1851 in Germany by Ernst Christian Friedrich Schering as an apothecary shop exporting pharmaceuticals.[1][2][3]. The U.S. arm, Schering Corporation, emerged after World War II when U.S. assets of Schering AG were seized in 1941 and privatized in 1952.[2][3]. In 1971, Schering Corporation merged with Plough, Inc. (founded 1908 by Abe Plough in Memphis), forming Schering-Plough, with Abe Plough as chairman.[1][2][3].
In New Zealand, SCHERING NZ LIMITED was registered on February 21, 1958 (NZBN: 9429040938295, company number 11171), operating as a limited company until its removal.[4]. Schering Plough Animal Health Ltd. handled animal health products from a base in Upper Hutt, later rebranded under MSD Animal Health.[6][8]. Key milestones for the group included 1960s product launches like Tinactin (1965) and Garamycin (1966), and acquisitions like White Laboratories (1957).[1][3].
Schering New Zealand operated in the traditional pharmaceutical sector, riding trends in antibiotics, allergy treatments, and animal health amid post-WWII globalization and mergers.[1][3]. Timing favored expansion in the 1950s-1970s with new drug introductions and Asia-Pacific growth, driven by market forces like rising demand for veterinary antibiotics (e.g., Nuflor for cattle) and consumer OTC products.[1][5]. It influenced New Zealand's pharma ecosystem through local manufacturing/distribution, later absorbed into Merck's network, supporting broader trends in merged big pharma dominating R&D and supply chains over standalone startups.[2][3][8]. No direct tech startup impact; instead, it exemplified legacy pharma's consolidation.
Schering New Zealand, as defunct entities, has no active future; operations folded into Merck/MSD post-2009 merger, with animal health continuing under MSD in Upper Hutt.[3][8]. Trends like biotech consolidation and veterinary tech (e.g., precision animal health) shape successors, potentially evolving influence via Merck's ongoing pharma dominance. This ties back to its origin as a pharma exporter, now legacy in a Merck-led ecosystem rather than independent growth.
Key people at Schering New Zealand.
